In their press release, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced that an ongoing Phase II proof-of-concept trial evaluating an investigational 8 mg dose of… Read More »Regeneron announces that its high-dose aflibercept (8mg) has met primary end-point in Phase II data for wet AMD.
Researchers from King’s College London, UK have published a systematic review and meta-analysis on individual participant data from RCT literature using evidence on ocriplasmin’s effect… Read More »A systematic review and meta-analysis on individual participant data, within 5 RCTs, on the treatment of ocriplasmin for vitreomacular adhesion resolution.
A research report in the journal Investigative Ophthalmology & Visual Sciences (IOVS) identifies a computational process to develop a new tool for diabetic macular edema… Read More »Genentech (Roche) has reported that a “deep learning” computational tool may be capable to use OCT predictive analytics for colour fundus photographs
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the November 2nd, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »November 2nd, 2017: “EURETINA-Brief”© Issue No. 164
An international research collaboration between US and EU clinical investigators, led by Duke University, Durham, North Carolina, has shown that adalimumab, an anti-TNF-α antagonist, marketed… Read More »Established rheumatoid arthritis (RA) drug from AbbVie (adalimumab) shows promise in the treatment of uveitis
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the January 18th, 2016 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »January 18th, 2016: “EURETINA-Brief”© Issue No. 125
Research from Tufts University, Boston, has indicated that evidence remains inconclusive in regards to whether or not zinc intake from foods and supplements is beneficial… Read More »The effects of zinc on the prevention and treatment of AMD are far from conclusive, according to a systematic review
t